{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:33:09Z","timestamp":1780536789202,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002412","name":"Xi\u2019an Jiaotong University","doi-asserted-by":"publisher","award":["2020YJ (ZYTS)625"],"award-info":[{"award-number":["2020YJ (ZYTS)625"]}],"id":[{"id":"10.13039\/501100002412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12282-024-01663-6","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T08:31:43Z","timestamp":1735288303000},"page":"369-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study"],"prefix":"10.1007","volume":"32","author":[{"given":"Peinan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-9192","authenticated-orcid":false,"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"1663_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Ca-a Cancer J Clin"},{"key":"1663_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546\u201353. https:\/\/doi.org\/10.1056\/NEJMoa012782.","journal-title":"N Engl J Med"},{"key":"1663_CR3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"J Clin Oncol"},{"key":"1663_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-9025-7","author":"A Fleissig","year":"2006","unstructured":"Fleissig A, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treatment. 2006. https:\/\/doi.org\/10.1007\/s10549-005-9025-7.","journal-title":"Breast Cancer Res Treatment"},{"key":"1663_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. J Natl Cancer Inst. 2006;98:599\u2013609. https:\/\/doi.org\/10.1093\/jnci\/djj158.","journal-title":"J Natl Cancer Inst"},{"key":"1663_CR6","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.2010.28.2491","volume":"28","author":"SR Land","year":"2010","unstructured":"Land SR, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28:3929\u201336. https:\/\/doi.org\/10.1200\/JCO.2010.28.2491.","journal-title":"J Clin Oncol"},{"key":"1663_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the american college of surgeons oncology group (alliance) acosog z0011 randomized trial. Ann Surg. 2016;264:413\u201320. https:\/\/doi.org\/10.1097\/SLA.0000000000001863.","journal-title":"Ann Surg"},{"key":"1663_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis the ACOSOG Z0011 (Alliance) randomized clinical trial. Jama-J the Am Med Assoc. 2017;318:918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"Jama-J the Am Med Assoc"},{"key":"1663_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/s1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310. https:\/\/doi.org\/10.1016\/s1470-2045(14)70460-7.","journal-title":"Lancet Oncol"},{"key":"1663_CR10","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","volume":"29","author":"C Tinterri","year":"2022","unstructured":"Tinterri C, et al. Preservation of axillary lymph nodes compared with complete dissection in t1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the sinodar-one multicenter randomized clinical trial. Ann Surg Oncol. 2022;29:5732\u201344. https:\/\/doi.org\/10.1245\/s10434-022-11866-w.","journal-title":"Ann Surg Oncol"},{"key":"1663_CR11","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/1097-0142(19821115)50:10<1979::AID-CNCR2820501002>3.0.CO;2-D","volume":"50","author":"E Frei","year":"1982","unstructured":"Frei E. Clinical cancer-research - an embattled species. Cancer. 1982;50:1979\u201392.","journal-title":"Cancer"},{"key":"1663_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/jjco\/hyz213","volume":"50","author":"T Shien","year":"2020","unstructured":"Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020;50:225\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyz213.","journal-title":"Jpn J Clin Oncol"},{"key":"1663_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/jco.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778\u201385. https:\/\/doi.org\/10.1200\/jco.2007.15.0235.","journal-title":"J Clin Oncol"},{"key":"1663_CR14","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1200\/jco.2001.19.22.4224","volume":"19","author":"JA van der Hage","year":"2001","unstructured":"van der Hage JA, et al. Preoperative chemotherapy in primary operable breast cancer: results from the european organization for research and treatment of cancer trial 10902. J Clin Oncol. 2001;19:4224\u201337. https:\/\/doi.org\/10.1200\/jco.2001.19.22.4224.","journal-title":"J Clin Oncol"},{"key":"1663_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer the ACOSOG Z1071 (Alliance) clinical trial. Jama-J Am Med Assoc. 2013;310:1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"Jama-J Am Med Assoc"},{"key":"1663_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.breast.2023.03.005","volume":"69","author":"M Heidinger","year":"2023","unstructured":"Heidinger M, Knauer M, Tausch C, Weber WP. Tailored axillary surgery - A novel concept for clinically node positive breast cancer. Breast. 2023;69:281\u20139. https:\/\/doi.org\/10.1016\/j.breast.2023.03.005.","journal-title":"Breast"},{"key":"1663_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clon.2007.10.004","volume":"20","author":"IH Kunkler","year":"2008","unstructured":"Kunkler IH, Canney P, van Tienhoven G, Russell NS. Elucidating the role of chest wall irradiation in \u201cintermediate-risk\u201d breast cancer: the MRC\/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20:31\u20134.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1663_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3:549\u201355. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4163.","journal-title":"JAMA Oncol"},{"key":"1663_CR19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/archsurg.2011.181","volume":"146","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Arch Surg. 2011;146:980\u2013980.","journal-title":"Arch Surg"},{"key":"1663_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30777-5","author":"EBCTCG","year":"2018","unstructured":"EBCTCG. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018. https:\/\/doi.org\/10.1016\/S1470-2045(17)30777-5.","journal-title":"Lancet Oncol"},{"key":"1663_CR21","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","volume":"7","author":"AV Barrio","year":"2021","unstructured":"Barrio AV, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event. JAMA Oncol. 2021;7:1851\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4394.","journal-title":"JAMA Oncol"},{"key":"1663_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncology. 2013;14:609\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(13)70166-9.","journal-title":"Lancet Oncology"},{"key":"1663_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/jco.2014.55.7827","volume":"33","author":"J-F Boileau","year":"2015","unstructured":"Boileau J-F, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258-U150. https:\/\/doi.org\/10.1200\/jco.2014.55.7827.","journal-title":"J Clin Oncol"},{"key":"1663_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"J-M Classe","year":"2019","unstructured":"Classe J-M, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173:343\u201352. https:\/\/doi.org\/10.1007\/s10549-018-5004-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1663_CR25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2024.0578","volume":"10","author":"G Montagna","year":"2024","unstructured":"Montagna G, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10:831\u20132. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0578.","journal-title":"JAMA Oncol"},{"key":"1663_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.seminoncol.2020.09.001","volume":"47","author":"F Magnoni","year":"2020","unstructured":"Magnoni F, et al. Axillary surgery in breast cancer: An updated historical perspective. Semin Oncol. 2020;47:341\u201352. https:\/\/doi.org\/10.1053\/j.seminoncol.2020.09.001.","journal-title":"Semin Oncol"},{"key":"1663_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.breast.2023.01.009","volume":"69","author":"AC Beck","year":"2023","unstructured":"Beck AC, Morrow M. Axillary lymph node dissection: Dead or still alive? Breast. 2023;69:469\u201375. https:\/\/doi.org\/10.1016\/j.breast.2023.01.009.","journal-title":"Breast"},{"key":"1663_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10549-011-1532-0","volume":"128","author":"B Gerber","year":"2011","unstructured":"Gerber B, et al. Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today? Breast Cancer Res Treat. 2011;128:613\u201324. https:\/\/doi.org\/10.1007\/s10549-011-1532-0.","journal-title":"Breast Cancer Res Treat"},{"key":"1663_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/01.sla.0000149429.39656.94","volume":"241","author":"SP Harlow","year":"2005","unstructured":"Harlow SP, et al. Prerandomization surgical training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial - A randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer. Ann Surg. 2005;241:48\u201354. https:\/\/doi.org\/10.1097\/01.sla.0000149429.39656.94.","journal-title":"Ann Surg"},{"key":"1663_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncology. 2013;14:297\u2013305. https:\/\/doi.org\/10.1016\/s1470-2045(13)70035-4.","journal-title":"Lancet Oncology"},{"key":"1663_CR31","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/bjs\/znad215","volume":"110","author":"C Tinterri","year":"2023","unstructured":"Tinterri C, et al. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. Br J Surg. 2023;110:1143\u201352. https:\/\/doi.org\/10.1093\/bjs\/znad215.","journal-title":"Br J Surg"},{"key":"1663_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.breast.2021.07.015","volume":"59","author":"S Cao","year":"2021","unstructured":"Cao S, et al. Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients. Breast (Edinburgh, Scotland). 2021;59:256\u201369. https:\/\/doi.org\/10.1016\/j.breast.2021.07.015.","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"1663_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071539","author":"PK Swarnkar","year":"2021","unstructured":"Swarnkar PK, Tayeh S, Michell MJ, Mokbel K. The Evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13071539.","journal-title":"Cancers (Basel)"},{"key":"1663_CR34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/bjs\/znac217","volume":"109","author":"ML Gasparri","year":"2022","unstructured":"Gasparri ML, et al. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg. 2022;109:857\u201363. https:\/\/doi.org\/10.1093\/bjs\/znac217.","journal-title":"Br J Surg"},{"key":"1663_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1245\/s10434-014-4034-6","volume":"22","author":"N Choy","year":"2015","unstructured":"Choy N, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol. 2015;22:377\u201382. https:\/\/doi.org\/10.1245\/s10434-014-4034-6.","journal-title":"Ann Surg Oncol"},{"key":"1663_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.0094","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016. https:\/\/doi.org\/10.1200\/jco.2015.64.0094.","journal-title":"J Clin Oncol"},{"key":"1663_CR37","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1245\/s10434-015-5052-8","volume":"23","author":"EJ Diego","year":"2016","unstructured":"Diego EJ, et al. Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol. 2016;23:1549\u201353. https:\/\/doi.org\/10.1245\/s10434-015-5052-8.","journal-title":"Ann Surg Oncol"},{"key":"1663_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.adro.2019.09.006","volume":"5","author":"DC Ling","year":"2020","unstructured":"Ling DC, Iarrobino NA, Champ CE, Soran A, Beriwal S. Regional recurrence rates with or without complete axillary dissection for breast cancer patients with node-positive disease on sentinel lymph node biopsy after neoadjuvant chemotherapy. Adv Radiat Oncol. 2020;5:163\u201370. https:\/\/doi.org\/10.1016\/j.adro.2019.09.006.","journal-title":"Adv Radiat Oncol"},{"key":"1663_CR39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","volume":"28","author":"MF Almahariq","year":"2021","unstructured":"Almahariq MF, et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual n1 nodal disease following neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28:930\u201340. https:\/\/doi.org\/10.1245\/s10434-020-08928-2.","journal-title":"Ann Surg Oncol"},{"key":"1663_CR40","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1097\/js9.0000000000000621","volume":"109","author":"T Zhu","year":"2023","unstructured":"Zhu T, et al. Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy: multicenter retrospective cohort study. Int J Surg. 2023;109:3383\u201394. https:\/\/doi.org\/10.1097\/js9.0000000000000621.","journal-title":"Int J Surg"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-024-01663-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:05:48Z","timestamp":1740038748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-024-01663-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1007\/s12282-024-01663-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest to disclose.Ethical approval and informed consent.As the SEER database used in this study does not contain personally identifiable information, patient informed consent is not needed. The study received an exemption from the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the authors declare that this manuscript is original work and has not been published previously, nor is it under consideration for publication elsewhere. All sources of funding and potential conflicts of interest have been disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}